FINANCE 301-MODULE-4-SLP

FINANCE 301-MODULE-4-SLP - FINANCE 301- EXTENDED MODULE 4...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
FINANCE 301- EXTENDED MODULE 4 SESSION LONG PROJECT DR. STEPHEN POLLARD Accentia Biopharmaceuticals, Inc. is looking for potential investors to invest in a new developing drug called SinuNase, which is in the pivotal third phase of its clinical trial. They are looking for investors to take advantage of the anticipated positive results. If the predicated results are positive, this should accelerate commercialization strategies. If funding goes according to schedule, this would give them the opportunity to market a new brand, nasal spray pump once trail phase in complete. SinuNase is a treatment for chronic sinusitis which is a disease that affects approximate 60 million people in the U.S. and Europe. There are always risks associated with an investment of this magnitude. Any new drug has to be approved by the Food and Drug Administration. This requires extensive research and development to ensure the drug is safe. If an investor decides to invest, his portfolio should be strong enough to handle unexpected changes if the drug should be
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 3

FINANCE 301-MODULE-4-SLP - FINANCE 301- EXTENDED MODULE 4...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online